超声引导下射频消融治疗原发性甲状旁腺功能亢进症的有效性与安全性:一项前瞻性研究
这项前瞻性研究纳入39例经生化和影像学证实由甲状旁腺病灶导致原发性甲状旁腺功能亢进症的患者,评估超声引导下射频消融的疗效与安全性。技术成功率为97.4%(38/39),术后6个月和12个月生化治愈率分别为82.1%(32/39)和84.4%(27/32),临床治愈率分别为100%(39/39)和96.9%(31/32)。作者认为超声引导下射频消融有效且安全,可能成为无法耐受或拒绝手术患者的替代治疗工具。
要点
- 超声引导下射频消融治疗原发性甲状旁腺功能亢进症技术成功率达97.4%(38/39)。
- 术后6个月和12个月生化治愈率分别为82.1%(32/39)和84.4%(27/32)。
- 术后6个月和12个月临床治愈率分别为100%(39/39)和96.9%(31/32)。
核心结论
- 超声引导下射频消融对原发性甲状旁腺功能亢进症患者有效且安全,可能成为无法耐受或拒绝手术患者的替代治疗工具。
研究设计与样本
- 前瞻性研究,纳入39例参与者(14例男性,25例女性;平均年龄59.5±15.3岁,范围18-87岁),于2018年9月1日至2021年1月31日入组,所有参与者均有经生化和影像学证实的导致原发性甲状旁腺功能亢进症的甲状旁腺病灶。
关键影像表现/征象
- 治疗前评估了原发性甲状旁腺功能亢进症结节的形态、边缘、大小、组成和位置等影像特征。
- 39个结节中38个实现完全消融,所有患者均在一次治疗中完成。
诊断标准与关键数值
- 技术成功率为97.4%(38/39),完全消融定义为39个结节中38个实现完全消融。
- 术后6个月生化治愈率为82.1%(32/39),术后12个月生化治愈率为84.4%(27/32)。
- 术后6个月临床治愈率为100%(39/39),术后12个月临床治愈率为96.9%(31/32)。
- 仅2.6%(1/39)的患者出现复发性原发性甲状旁腺功能亢进症。
- 技术成功消融后1、3、6、12个月分别有44.7%(17/38)、34.3%(12/35)、15.8%(6/38)、12.5%(4/32)的参与者出现血钙正常而甲状旁腺激素水平升高。
临床应用与阅片要点
- 作者认为超声引导下射频消融可能成为无法耐受或拒绝手术的原发性甲状旁腺功能亢进症患者的替代治疗工具。
- 术后需监测血清完整甲状旁腺激素、钙、磷水平及甲状旁腺结节体积和原发性甲状旁腺功能亢进症相关症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) in patients with primary hyperparathyroidism (PHPT).
MATERIALS AND METHODS: This prospective study enrolled 39 participants (14 male, 25 female; mean age, 59.5 ± 15.3 [range, 18-87] years) between September 1, 2018, and January 31, 2021. All participants had parathyroid lesions causing PHPT, proven biochemically and through imaging. The imaging features of the PHPT nodules, including the shape, margin, size, composition, and location, were evaluated before treatment. Serum intact parathyroid hormone, calcium, and phosphorus levels; parathyroid nodule volume; and PHPT-related symptoms were recorded before and after treatment. We calculated the technical success, biochemical cure, and clinical cure rates for these patients. Complications were evaluated during and after the ablation.
RESULTS: Complete ablation was achieved in 38 of the 39 nodules in the 39 enrolled participants. All the patients were treated in one session. The technical success rate was 97.4% (38/39). The mean follow-up duration was 13.2 ± 4.6 (range, 6.0-24.9) months. At 6 and 12 months post-RFA, the biochemical cure rates were 82.1% (32/39) and 84.4% (27/32), respectively, and the clinical cure rates were 100% (39/39) and 96.9% (31/32), respectively. Only 2.6% (1/39) of the patients had recurrent PHPT. At 1, 3, 6, and 12 months after technically successful RFA, 44.7% (17/38), 34.3% (12/35), 15.8% (6/38), and 12.5% (4/32) of participants, respectively, had elevated eucalcemic parathyroid hormone levels. Recurrent laryngeal nerve paralysis occurred in 5.1% (2/39) of the patients, who recovered spontaneously within 1-3 months.
CONCLUSION: US-guided RFA was effective and safe for PHPT patients. RFA may be an alternative treatment tool for patients who cannot tolerate or refuse to undergo surgery.
引用
- Chai HH, Zhao Y, Zeng Z, et al. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism: A Prospective Study. Korean J Radiol. 2022. PMID: 35506529. doi:10.3348/kjr.2021.0716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。